These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15551258)

  • 1. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
    Hinterhuber L; Graziadei IW; Kähler CM; Jaschke W; Vogel W
    Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C; Gülberg V; Gerbes AL
    Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
    Sato A; Maie K; Ohno Y; Yoshida T; Ito E; Tanabe Y; Aizawa Y
    Int Heart J; 2011; 52(4):243-5. PubMed ID: 21828952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
    Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
    Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
    Sağ S; Yeşilbursa D; Güllülü S
    Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G; von Hunnius P
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
    Grander W; Eller P; Fuschelberger R; Tilg H
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
    Barth F; Gerber PJ; Reichen J; Dufour JF; Nicod LP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1117-9. PubMed ID: 16957519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
    Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
    Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
    Muraoka H; Imamura T; Hatano M; Maki H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2015; 56(4):471-3. PubMed ID: 26084462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.
    Clift PF; Townend JN; Bramhall S; Isaac JL
    Transplantation; 2004 Jun; 77(11):1774-5. PubMed ID: 15201683
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
    Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
    Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
    Halank M; Miehlke S; Hoeffken G; Schmeisser A; Schulze M; Strasser RH
    Transplantation; 2004 Jun; 77(11):1775-6. PubMed ID: 15201684
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
    Ashfaq M; Chinnakotla S; Rogers L; Ausloos K; Saadeh S; Klintmalm GB; Ramsay M; Davis GL
    Am J Transplant; 2007 May; 7(5):1258-64. PubMed ID: 17286619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
    Hino T; Hayashida A; Okahashi N; Wada N; Watanabe N; Obase K; Neishi Y; Kawamoto T; Okura H; Yoshida K
    Intern Med; 2009; 48(8):597-600. PubMed ID: 19367055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
    Eriksson C; Gustavsson A; Kronvall T; Tysk C
    J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
    Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
    Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
    Neuhofer W; Gülberg V; Gerbes AL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
    Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
    Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.